All In Biotech

Drug Trial Radar · NCT02165826

Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD

A Multicenter, Randomized, Double-blind Phase 3 Study to Evaluate Tolerability and Pharmacokinetics of 500 μg Roflumilast Once Daily With an Up-titration Regimen in COPD, Including an Open-label Down-titration Period Evaluating Tolerability and Pharmacokinetics of 250 μg Roflumilast Once Daily in Subjects Not Tolerating 500 μg Roflumilast Once-daily

Last checked: Nov 19, 2026Latest source record: Apr 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,323 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,323

Actual

Start

May 1, 2014

Primary completion

Sep 1, 2015

Study completion Sep 1, 2015

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 18, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate discontinuation rates of roflumilast using an up-titration regimen for the first 4 weeks of treatment compared with continuous treatment of 500 μg one daily (OD) during the entire 12-week main period, and to evaluate if participants who do not tolerate roflumilast 500 μg OD have a drug exposure with 250 μg roflumilast OD similar to that observed in other participants with the 500 μg OD dose.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • RoflumilastDrug

    Roflumilast tablets

  • Roflumilast PlaceboDrug

    Roflumilast placebo-matching tablets

  • Standard of Care COPD TreatmentDrug

    The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any ReasonTime frame: Baseline to Week 12 (Main Period)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Bardejov, Slovakia

  • Site not named

    Spišská Nová Ves, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.